STX Shield Therapeutics Plc

TIDMSTX

Shield Therapeutics PLC

25 February 2022

Shield Therapeutics plc

("Shield" or the "Company" or the "Group")

Investor Presentation

London, UK - 25 February 2022: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on treating iron deficiency with its lead product Accrufer(R)/Ferracru(R), announces that it will provide a live investor presentation on Thursday 3 March 2022 at 4.30pm (GMT).

Chief Executive Officer, Greg Madison will present alongside Chief Financial Officer, Hans-Peter Rudolf and Chief Medical Officer, Dr José Menoyo to provide an update to investors following the recent trading statement. Investors can sign up to Investor Meet Company for free and request to meet Shield Therapeutics plc via the following link: https://www.investormeetcompany.com/shield-therapeutics-plc/register-investor

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of regulations and information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards. No new price sensitive information will be disclosed, and a PDF of the presentation will be uploaded to the Company's website.

For further information please contact:

 
 Shield Therapeutics plc                                        www.shieldtherapeutics.com 
 Greg Madison, CEO                                                    +44 (0) 191 511 8500 
 Hans-Peter Rudolf, CFO 
 
   Nominated Adviser and Joint 
   Broker 
 Peel Hunt LLP 
 James Steel/Christopher Golden                                        +44 (0)20 7418 8900 
 
   Joint Broker 
   finnCap Ltd 
   Geoff Nash/ George Dollemore/Alice 
   Lane/Nigel Birks                                                    +44 (0)20 7220 0500 
 
 Financial PR & IR Advisor 
 Walbrook PR 
 Lianne Applegarth/Alice Woodings             +44 (0)20 7933 8780 or shield@walbrookpr.com 
 
 Investor Contact (US Advisor) 
  LifeSci Advisors, LLC 
  John Mullaly                             +1 617 429 3548 or jmullaly@lifesciadvisors.com 
 

About Accrufer (R) /Feraccru (R)

Accrufer(R)/Feraccru(R) (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer(R)/Feraccru(R) has a novel mechanism of absorption compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer(R)/ Feraccru(R) , including the product label, can be found at: www.accrufer.com and www.feraccru.com

About Shield Therapeutics plc

Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer(R)/Feraccru(R) (ferric maltol). The Group has launched Accrufer(R) in the US and Feraccru(R) is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer(R) / Feraccru(R) in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.

Accrufer(R)/Feraccru(R) has patent coverage until the mid-2030s

Accrufer(R)/Feraccru(R) are registered trademarks of the Shield Group

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUSRKRUNUUUAR

(END) Dow Jones Newswires

February 25, 2022 02:01 ET (07:01 GMT)

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024

Shield Therapeutics (LSE:STX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024